TLIS

Insider Trades

Name	Value	Action	Price	Current Price
Leonard Braden Michael10 Percent Owner $51k13.2k shares BuyAug 26, 2024 $3.90 --
Leonard Braden Michael10 Percent Owner $4.8k1.2k shares BuyAug 28, 2024 $3.96 --
Leonard Braden Michael10 Percent Owner $642151 shares BuyAug 30, 2024 $4.25 --
Leonard Braden Michael10 Percent Owner $2.0k500 shares BuySep 3, 2024 $4.00 --
Leonard Braden Michael10 Percent Owner $7.1k5.1k shares BuySep 5, 2024 $1.40 --
Leonard Braden Michael10 Percent Owner $37k25k shares BuySep 6, 2024 $1.48 --

Trade TLIS

About Talis Biomedical Corporation

Talis Biomedical Corporation specializes in molecular diagnostics, focusing on the creation of its Talis One system. This system is being developed to address and resolve existing limitations within current point-of-care diagnostic testing technologies for infectious diseases. The company currently provides the Talis One COVID-19 Test System, which is specifically designed for the detection of SARS-CoV-2, the virus responsible for COVID-19. Beyond this, Talis is also developing a range of Talis One assay kits to target respiratory infections, infections related to women's health, and sexually transmitted infections. Its pipeline further includes other diagnostic tests for various respiratory pathogens, such as a panel test capable of identifying influenza A, influenza B, and respiratory syncytial virus. Established in 2013, Talis Biomedical Corporation is headquartered in Menlo Park, California.

CEO: Rebecca Markovich
IPO Date: Feb 12, 2021

Market Data

Volume: 1.7K

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsAug 18